^
Association details:
| Biomarker: | CCDC6-ALK fusion |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma
Excerpt:
A 10-year-old boy with progressive stridor was found to have metastatic MTC...Molecular testing revealed a novel CCDC6-ALK fusion. His therapy was changed to crizotinib and then to alectinib for improved tolerability….He remains on alectinib with ongoing response.
DOI:
10.1089/thy.2019.0041
